The effects of Omega-3 fatty acids and vitamin D supplementation on the quality of life and blood inflammation markers in newly diagnosed breast cancer women: An open-labelled randomised controlled trial

IF 2.9 Q3 NUTRITION & DIETETICS

Clinical nutrition ESPEN Pub Date : 2024-11-20 DOI:10.1016/j.clnesp.2024.11.014

Heba F. Almassri , Azidah Abdul Kadir , Mohammed Srour , Leng Huat Foo

{"title":"The effects of Omega-3 fatty acids and vitamin D supplementation on the quality of life and blood inflammation markers in newly diagnosed breast cancer women: An open-labelled randomised controlled trial","authors":"Heba F. Almassri , Azidah Abdul Kadir , Mohammed Srour , Leng Huat Foo","doi":"10.1016/j.clnesp.2024.11.014","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aims</h3><div>Nutritional intervention is one of the primary steps to improvement of health status and quality of life (QoL) in patients with cancer treated by chemotherapy. There is limited evidence on the potential nutritional intervention to complement active oncological treatment strategies in breast cancer (BC) patients in developing countries. The aim of the present study was to assess the effects of omega-3 fatty acids (ω3) and vitamin D<sub>3</sub> (VitD) supplementations on the QoL and blood inflammation markers of tumor necrosis factor-alpha (TNF-α) and high-sensitive C-reactive protein (hsCRP) assessed among women newly diagnosed with BC in the Gaza Strip, Palestine.</div></div><div><h3>Methods</h3><div>A total of 88 BC women were randomly assigned into one of four groups: i) omega-3 fatty acid (ω3) group; ii) vitamin D (VitD) group; iii) ω3+VitD group, and iv) the control. Participants were received either two 300 mg ω3 capsules daily, or one 50,000IU VitD tablet weekly, or both supplementation for 9-weeks. The QoL status was assessed by the European Organization for Research and Treatment of Cancer (EORTC) instruments of QLQ-C30 and QLQ-BR23 tools, while blood inflammatory markers of TNF-α hsCRP were used. All measurements were taken from baseline to the end of the intervention period. The detailed procedures of the present study were registered on ClinicalTrial.gov with the identifier NCT05331807.</div></div><div><h3>Results</h3><div>At the end of the trial, participants in the ω3+VitD group showed a significant increase in overall global health status (p < 0.01) compared to other groups. Additionally, this group showed significantly higher functional scores (all p < 0.05) and lower scores for fatigue (p < 0.01), nausea and vomiting, pain, and appetite loss (all p < 0.05) at the end of the trial compared to baseline. Furthermore, comparisons between the intervention groups revealed a significant difference in blood concentrations of TNF-α and hsCRP (p < 0.05). These significant differences were identified in hsCRP between ω3 and control groups (p < 0.01). The ω3+VitD group demonstrated a significant reduction in both hsCRP and TNF-α levels (both p < 0.05) from baseline. No significant changes in blood inflammatory markers were observed within the ω3 or VitD groups alone.</div></div><div><h3>Conclusion</h3><div>Participants receiving daily ω3 and weekly VitD supplementation for 9 weeks showed a significant improved in QoL and blood inflammation markers among the newly diagnosed BC during their chemotherapy treatment.</div></div>","PeriodicalId":10352,"journal":{"name":"Clinical nutrition ESPEN","volume":"65 ","pages":"Pages 64-75"},"PeriodicalIF":2.9000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical nutrition ESPEN","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405457724015237","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background and aims

Nutritional intervention is one of the primary steps to improvement of health status and quality of life (QoL) in patients with cancer treated by chemotherapy. There is limited evidence on the potential nutritional intervention to complement active oncological treatment strategies in breast cancer (BC) patients in developing countries. The aim of the present study was to assess the effects of omega-3 fatty acids (ω3) and vitamin D₃ (VitD) supplementations on the QoL and blood inflammation markers of tumor necrosis factor-alpha (TNF-α) and high-sensitive C-reactive protein (hsCRP) assessed among women newly diagnosed with BC in the Gaza Strip, Palestine.

Methods

A total of 88 BC women were randomly assigned into one of four groups: i) omega-3 fatty acid (ω3) group; ii) vitamin D (VitD) group; iii) ω3+VitD group, and iv) the control. Participants were received either two 300 mg ω3 capsules daily, or one 50,000IU VitD tablet weekly, or both supplementation for 9-weeks. The QoL status was assessed by the European Organization for Research and Treatment of Cancer (EORTC) instruments of QLQ-C30 and QLQ-BR23 tools, while blood inflammatory markers of TNF-α hsCRP were used. All measurements were taken from baseline to the end of the intervention period. The detailed procedures of the present study were registered on ClinicalTrial.gov with the identifier NCT05331807.

Results

At the end of the trial, participants in the ω3+VitD group showed a significant increase in overall global health status (p < 0.01) compared to other groups. Additionally, this group showed significantly higher functional scores (all p < 0.05) and lower scores for fatigue (p < 0.01), nausea and vomiting, pain, and appetite loss (all p < 0.05) at the end of the trial compared to baseline. Furthermore, comparisons between the intervention groups revealed a significant difference in blood concentrations of TNF-α and hsCRP (p < 0.05). These significant differences were identified in hsCRP between ω3 and control groups (p < 0.01). The ω3+VitD group demonstrated a significant reduction in both hsCRP and TNF-α levels (both p < 0.05) from baseline. No significant changes in blood inflammatory markers were observed within the ω3 or VitD groups alone.

Conclusion

Participants receiving daily ω3 and weekly VitD supplementation for 9 weeks showed a significant improved in QoL and blood inflammation markers among the newly diagnosed BC during their chemotherapy treatment.

查看原文本刊更多论文

补充 Omega-3 脂肪酸和维生素 D 对新诊断乳腺癌妇女的生活质量和血液炎症指标的影响：一项开放标签随机对照试验。

背景和目的：营养干预是改善化疗癌症患者健康状况和生活质量（QoL）的主要措施之一。发展中国家的乳腺癌（BC）患者可能通过营养干预来补充积极的肿瘤治疗策略，但这方面的证据有限。本研究旨在评估补充欧米伽-3 脂肪酸（ω3）和维生素 D3（VitD）对巴勒斯坦加沙地带新诊断为乳腺癌的妇女的 QoL 以及肿瘤坏死因子-α（TNF-α）和高敏 C 反应蛋白（hsCRP）等血液炎症指标的影响：将 88 名 BC 妇女随机分配到以下四组中的一组：i) ω-3 脂肪酸（ω3）组；ii) 维生素 D（VitD）组；iii) ω3+VitD 组；iv) 对照组。参与者每天服用两粒 300 毫克 ω3 胶囊，或每周服用一粒 50,000IU 维生素 D 片剂，或同时服用两种药物，为期 9 周。QoL状况由欧洲癌症研究和治疗组织（EORTC）的QLQ-C30和QLQ-BR23工具进行评估，同时使用血液炎症指标TNF-α hsCRP。所有测量均从基线到干预期结束进行。本研究的详细程序已在 ClinicalTrial.gov 上注册，标识符为 NCT05331807：试验结束时，ω3+VitD 组的参与者总体健康状况显著改善（p 结论：ω3+VitD 组的参与者总体健康状况显著改善（p 结论：ω3+VitD 组的参与者总体健康状况显著改善（p 结论）：在化疗期间接受每日ω3和每周维生素D补充剂治疗9周的新确诊BC患者的QoL和血液炎症指标均有明显改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical nutrition ESPEN NUTRITION & DIETETICS-

CiteScore

4.90

自引率

3.30%

发文量

512

期刊介绍： Clinical Nutrition ESPEN is an electronic-only journal and is an official publication of the European Society for Clinical Nutrition and Metabolism (ESPEN). Nutrition and nutritional care have gained wide clinical and scientific interest during the past decades. The increasing knowledge of metabolic disturbances and nutritional assessment in chronic and acute diseases has stimulated rapid advances in design, development and clinical application of nutritional support. The aims of ESPEN are to encourage the rapid diffusion of knowledge and its application in the field of clinical nutrition and metabolism. Published bimonthly, Clinical Nutrition ESPEN focuses on publishing articles on the relationship between nutrition and disease in the setting of basic science and clinical practice. Clinical Nutrition ESPEN is available to all members of ESPEN and to all subscribers of Clinical Nutrition.